Finance

Beta
Lists
SPRY:NASDAQ
ARS Pharmaceuticals Inc
$8.02
+1.01%
(+0.080) 1D
Jul 2, 12:38:07 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SPRY...
Open
$8.14
High
$8.35
Low
$8.00
Mkt. cap
796.41M
Avg. vol.
1.87M
Volume
787.18K
52-wk high
$18.63
52-wk low
$6.66
EPS
-$2.00
Beta
0.95
Shares outstanding
99.30M
No. of employees
157
Open
$8.14
High
$8.35
Low
$8.00
Mkt. cap
796.41M
Avg. vol.
1.87M
Volume
787.18K
52-wk high
$18.63
52-wk low
$6.66
EPS
-$2.00
Beta
0.95
Shares outstanding
99.30M
No. of employees
157
News stories
From sources across the web
About ARS Pharmaceuticals Inc
CEO-
Employees157
Founded2015
Headquarters-
SectorBiotechnology
Websitears-pharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to SPRY in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for SPRY in the last 3 months.
Highest
Current $8.02
$30.00 (+274.06%)
Average
$28.33 (+253.24%)
Lowest
$25.00 (+211.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Joshua Schimmer
Cantor Fitzgerald
Buy
Maintained
$30.00
+274.1%
06/24/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
06/25/2026
Carl Byrnes
Northland Securities
Buy
Maintained
$25.00
+211.7%
04/15/2026
Kyle Bauser
Roth MKM
Buy
Reiterated
$30.00
+274.1%
04/14/2026
Ryan Deschner
Raymond James
Buy
Maintained
-
-
01/09/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
15.72M
32.50M
28.09M
22.68M
Cost of goods sold
9.02M
10.94M
9.60M
10.62M
Cost of revenue
9.02M
10.94M
9.60M
10.62M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
54.31M
74.75M
59.96M
72.20M
Operating expense
54.31M
74.75M
59.96M
72.20M
Total operating expenses
63.33M
85.69M
69.55M
82.83M
Operating income
-47.61M
-53.19M
-41.46M
-60.14M
Other non operating income
2.73M
2.04M
-3.49M
-
EBT including unusual items
-44.88M
-51.15M
-41.40M
-60.62M
EBT excluding unusual items
-44.88M
-51.15M
-36.88M
-60.62M
Income tax expense
-
-
-80.00K
-
Effective tax rate
-
-
0.19%
-
Other operating expenses
-
-
-
-
Net income
-44.88M
-51.15M
-41.32M
-60.62M
Net profit margin
-285.57%
-157.38%
-147.13%
-267.26%
Earnings per share
-0.46
-0.52
-0.42
-0.61
Interest and investment income
-
-
10.67M
1.97M
Interest expense
-
-
-2.60M
-2.44M
Net interest expenses
-
-
8.07M
-473.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-47.34M
-52.80M
-41.05M
-59.75M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer